Search

everythinglearnresearchcommunity

for

Search:↓

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

The conversation is about the debate over the existence of Post-Finasteride Syndrome (PFS) and its symptoms, with some users skeptical about PFS and others discussing side effects like erectile dysfunction and gynecomastia from hair loss treatments like finasteride. Specific treatments mentioned include finasteride, viagra, and a joke about using a popsicle stick for erectile support.

The user experienced a panic attack after adding 5% topical minoxidil to their routine, which already included oral finasteride and minoxidil, and microneedling. They are seeking advice on whether microneedling increased absorption and if the anxiety attacks will subside.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

The conversation discusses a hair loss treatment regimen that includes scalp massage, derma rolling, saw palmetto, rosemary, peppermint oil, pumpkin seed oil, and various supplements like vitamins C and D, multivitamins, biotin, collagen, and fish oil. The user is asking if the treatment has led to hair regrowth.

The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.

Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.

The user shared their hair loss journey, using 0.5mg finasteride, topical minoxidil, and dermarolling initially, then increasing to 1mg finasteride and adding 2.5mg oral minoxidil. They experienced significant regrowth but are currently facing a prolonged shedding phase, hoping for stabilization and regrowth.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

The conversation is about concerns and advice regarding microneedling for hair loss, with potential risks like chronic inflammation, scarring, and folliculitis. The user has been using minoxidil, finasteride, and stemoxydine with good results and is considering adding microneedling, with recommendations for using a dermastamp or pen.

A user shared their experience with hair loss treatments, including I-PRF injections, mesotherapy, and a topical solution containing Minoxidil and Finasteride. After experiencing side effects, they decided to stop the medicinal treatments and focus on natural alternatives like I-PRF, microneedling, and essential oils.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user experienced initial hair density improvement with finasteride, but later felt scalp pain and a plateau in results. They added alfatradiol for scalp inflammation and divi scalp serum to their routine, and are curious if others have similar experiences.

A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A user humorously suggests an extreme hair loss treatment regimen involving multiple medications and therapies, including Dutasteride, Minoxidil, RU58841, and others, claiming it would prevent hair loss but with potential side effects like gynecomastia. The conversation highlights concerns about safety, side effects, and the effectiveness of such a comprehensive approach.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The conversation discusses the cost and insurance coverage of a comprehensive hormone and DHT blood panel for hair loss, with a focus on finasteride treatment. The user seeks a cheaper alternative to a $700 panel recommended in a video.

The conversation provides a detailed list of blood tests recommended before starting finasteride to establish a baseline for monitoring potential side effects. A shorter list is also provided for those with limited funds, and the user shares personal experience of using finasteride without issues for about nine years.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

The conversation discusses using soy isoflavones and capsaicin for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation humorously discusses starting oral microneedling for hair loss, with mentions of side effects like internal bleeding and abdominal pain. It also references using treatments like minoxidil and finasteride, with exaggerated and satirical comments on their effects.

A user's successful hair regrowth journey using a cocktail of finasteride, minoxidil, and ketoconazole. The user started seeing noticeable results after 8 months and also incorporated saw palmetto, biotin, keratin, and dermarolling into their routine.

A 23-year-old experiencing diffuse hair thinning has chosen a treatment stack including topical finasteride, a blend of rosemary, peppermint, and pumpkin seed oils, procyanidine B2 spray, ketoconazole shampoo, and scalp massages. They avoid minoxidil due to family history of side effects and oral finasteride due to high estrogen levels.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.